29 May , 2026 By : Debdeep Gupta
Indoco Remedies share price will remain in focus on May 29 after the pharmaceutical company received the European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority (Berlin) for its manufacturing facility in Baddi, Himachal Pradesh.
The certification has been granted for the company’s Oral Solid Dosage (OSD) manufacturing facility (Plant III). The inspection was conducted between April 22 and April 27, 2026.
The EU GMP certification confirms that the facility complies with Good Manufacturing Practice requirements as referred to in the EC Directive.
“The EU GMP certification for our formulations manufacturing plant is a testament to our commitment to delivering high quality products to patients across the globe," said Aditi Panandikar, Managing Director – Indoco Remedies
Earlier this month, the company’s solid oral dosage manufacturing facility (Unit I) at Baddi had also received EU GMP certification from the Malta Medicines Authority.
In the previous trading session, Indoco Remedies shares closed at Rs 203.75, higher by Rs 9.90 or 5.11 percent. The stock touched a 52-week high of Rs 348.10 on July 17, 2025, and a 52-week low of Rs 163.70 on March 30, 2026.
At current levels, the stock is trading 41.47 percent below its 52-week high and 24.47 percent above its 52-week low. The company’s market capitalisation stands at Rs 1,880.69 crore.
0 Comment